TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3719595

Group type: EXPERIMENTAL
Intervention: intrapleural BCG (5 patients 16 X 10(6), 25 patients 32 X 10(6), and 26 patients 64 X 10(6) culturable particles)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: intrapleural BCG
Number of subjects: 99

Group type: COMPARATOR
Intervention: historical control population
Number of subjects: 99
Study: 29242014

Group type: EXPERIMENTAL
Intervention: Omalizumab combined with multifood oral immunotherapy (n=36)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 48
Study: 29209154

Group type: EXPERIMENTAL
Intervention: Caffeinated supplement
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Non-caffeinated supplement
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25785955

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR) at 1 level
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR) at 2 levels
Number of subjects: 413

Group type: COMPARATOR
Intervention: Total Disc Replacement (TDR)
Number of subjects: 413
Study: 22965657

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300 U
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 20854954

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus GP IIb/IIIa inhibitor
Number of subjects: 329

Group type: COMPARATOR
Intervention: Heparin plus GP IIb/IIIa inhibitor
Number of subjects: 329
Study: 18238736

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 50,000 IU once weekly for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16359588

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX-A)
Number of subjects: 61
Study: 12744911

Group type: EXPERIMENTAL
Intervention: High 5, Low Fat Program (H5LF)
Number of subjects: 738
Study: 10776745

Group type: EXPERIMENTAL
Intervention: Artemether 6 mg/kg orally six times once every 3 weeks
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Artemether 6 mg/kg
Number of subjects: 354
Study: 8725415

Group type: EXPERIMENTAL
Intervention: 6% hetastarch
Number of subjects: 47

Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 47
Study: 11885225

Group type: EXPERIMENTAL
Intervention: Self brushing with acidulated phosphate fluoride (APF) gel (pH 5.6; concentration: 4520 ppm of ion F‐)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 240
Study: 3190292

Group type: EXPERIMENTAL
Intervention: New catheter at a new site every 3 days (Group 1)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Changing catheters over a guide-wire (Group 2)
Number of subjects: 379
Study: 31044320

Group type: EXPERIMENTAL
Intervention: Real tDCS stimulation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 9
Study: 28288434

Group type: EXPERIMENTAL
Intervention: Intensive education program and switch to a 4mm pen needle
Number of subjects: 75
Study: 24947808

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 times per week for 3 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 60
Study: 23763894

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline EEG power measurements
Number of subjects: 0
Study: 21157477

Group type: EXPERIMENTAL
Intervention: Walnuts
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 31
Study: 19805710

Group type: EXPERIMENTAL
Intervention: Behavioral plus nutrition education intervention (Be In CHARGE!)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nutrition education intervention alone
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 79
Study: 17692744

Group type: EXPERIMENTAL
Intervention: BG9928 (3, 15, 75, or 225 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BG9928 (15, 75, or 225 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BG9928 (3 to 225 mg)
Number of subjects: 50
Study: 15174010

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) 0.4 mg/kg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) 0.4 mg/kg orally coadministered with levodopa (0.5 mg/kg/hr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) coadministered with levodopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD)
Number of subjects: 0
Study: 11435843

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 43
Study: 9555659

Group type: EXPERIMENTAL
Intervention: IgAN group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Other glomerulonephritis group
Number of subjects: 32
Study: 7501342

Group type: EXPERIMENTAL
Intervention: Thick laminaria tents
Number of subjects: 93

Group type: COMPARATOR
Intervention: 3-mm Hypan tents
Number of subjects: 93

Group type: COMPARATOR
Intervention: 3-mm magnesium sulfate devices
Number of subjects: 93
Study: 2102133

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Indomethacin (50 mg/b.i.d.)
Number of subjects: 8
Study: 371738

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and antrectomy (TVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative patients
Number of subjects: 0
Study: 30101386

Group type: EXPERIMENTAL
Intervention: Smoke-Free Homes: Some Things are Better Outside (minimal intervention)
Number of subjects: 1506
Study: 28768250

Group type: EXPERIMENTAL
Intervention: L. gasseri OLL2716 group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 116
Study: 25173349

Group type: EXPERIMENTAL
Intervention: EXTRA programme
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 23109617

Group type: EXPERIMENTAL
Intervention: Fast Mental Health Triage Tool (FMHT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: No tool or scale
Number of subjects: 270
Study: 21476936

Group type: EXPERIMENTAL
Intervention: 5-mm needle
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 8-mm needle
Number of subjects: 130

Group type: COMPARATOR
Intervention: Both needles
Number of subjects: 130
Study: 18264616

Group type: EXPERIMENTAL
Intervention: Integrated infant and young child feeding counseling course
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 16929706

Group type: EXPERIMENTAL
Intervention: Hypertensive/dependent group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Hypertensive/nondependent group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normotensive/dependent group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Normotensive/nondependent group
Number of subjects: 106
Study: 12713981

Group type: EXPERIMENTAL
Intervention: Pelvic RT (46 Gy)
Number of subjects: 714

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 714
Study: 11009049

Group type: EXPERIMENTAL
Intervention: BIAsp30 (0.2 U x kg(-1) bodyweight)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BHI30 (0.2 U x kg(-1) bodyweight)
Number of subjects: 24
Study: 1661645

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.07 units/kg at night)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7041324

Group type: EXPERIMENTAL
Intervention: Carbimazole 80 mg daily for two months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30968066

Group type: EXPERIMENTAL
Intervention: 2.5% w/w calcium sodium phosphosilicate (CSPS) dentifrice (test)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 8% w/w arginine dentifrice (comparator)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 151
Study: 29623143

Group type: EXPERIMENTAL
Intervention: Nalbuphine (15 μg·kg‐1·ml‐1) with flurbiprofen
Number of subjects: 158

Group type: COMPARATOR
Intervention: Sufentanil with flurbiprofen
Number of subjects: 158
Study: 26887663

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 25149899

Group type: EXPERIMENTAL
Intervention: Needle aponeurotomy combined with triamcinolone injections
Number of subjects: 44

Group type: COMPARATOR
Intervention: Needle aponeurotomy alone
Number of subjects: 44
Study: 22423956

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation under general anesthesia (Group GC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gasless technique under general anesthesia (Group GG)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gasless technique under epidural anesthesia (Group EG)
Number of subjects: 57
Study: 20074380

Group type: EXPERIMENTAL
Intervention: Capillary electrophoresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agarose gel electrophoresis
Number of subjects: 0
Study: 17663615

Group type: EXPERIMENTAL
Intervention: Coping and communication-enhancing intervention (CCI)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Supportive counseling (SC)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 353
Study: 16026123

Group type: EXPERIMENTAL
Intervention: Celecoxib and rofecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant drugs
Number of subjects: 0
Study: 11802045

Group type: EXPERIMENTAL
Intervention: Ketoprofen (0.5 mg/kg bolus intravenously, followed by 3 mg/kg continuous infusion over 24 hours, and 3 to 5 mg/kg per day at home)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ketoprofen combined with paracetamol-codeine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal saline and oxycodone (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 102
Study: 10073786

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 7494612

Group type: EXPERIMENTAL
Intervention: Conventional cellulose membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cellulose triacetate membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 2269542

Group type: EXPERIMENTAL
Intervention: DPI 201‐106 (20 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DPI 201‐106 (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6308702

Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg i.v.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Apomorphine (20 micrograms/kg/hr) for 40 min by i.v. infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vasopressin rise
Number of subjects: 12
Study: 31550197

Group type: EXPERIMENTAL
Intervention: Computer-Based Counseling Program (CARE+ Kenya)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Risk-assessment only control
Number of subjects: 236
Study: 28799413

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD-HIV)
Number of subjects: 10
Study: 26857924

Group type: EXPERIMENTAL
Intervention: Standard concomitant administration of bevacizumab with chemotherapy (mFOLFOX/OXXEL regimen)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Experimental sequential bevacizumab given 4 days before chemotherapy
Number of subjects: 230
Study: 24556231

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 23218935

Group type: EXPERIMENTAL
Intervention: Bupivacaine .5% with ketorolac .6 mg/hour
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine .5% with hydromorphone .04 mg/hour
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine .5% (active control)
Number of subjects: 60
Study: 20824678

Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin once daily for 18 weeks
Number of subjects: 801

Group type: COMPARATOR
Intervention: 100 mg sitagliptin once daily for 18 weeks
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin plus metformin
Number of subjects: 801

Group type: COMPARATOR
Intervention: 100 mg sitagliptin plus metformin
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 801
Study: 18410225

Group type: EXPERIMENTAL
Intervention: Calcium citrate 1000 mg/day + vitamin D(2) 1000 IU
Number of subjects: 302

Group type: COMPARATOR
Intervention: Calcium citrate 1000 mg/day + placebo
Number of subjects: 302
Study: 15763608

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12724503

Group type: EXPERIMENTAL
Intervention: Sertraline (N=70)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (N=67)
Number of subjects: 137
Study: 10556125

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NPPV in patients with COPD
Number of subjects: 56
Study: 8732628

Group type: COMPARATOR
Intervention: Leukocyte count
Number of subjects: 154

Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fibrinogen
Number of subjects: 154

Group type: COMPARATOR
Intervention: Leukocyte count, fibrinogen, and CRP
Number of subjects: 154
Study: 1930344

Group type: EXPERIMENTAL
Intervention: Kava extract WS 1490 (Laitan) 3 x 100 mg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 58
Study: 7149056

Group type: EXPERIMENTAL
Intervention: Intravenous haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral haloperidol
Number of subjects: 0
Study: 31776310

Group type: EXPERIMENTAL
Intervention: Mail-based intervention using the TAKE10! Program (monthly mail with self-check sheets and feedback for 5 months)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 143
Study: 28013054

Group type: EXPERIMENTAL
Intervention: CCT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 114
Study: 27102290

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 110
Study: 24524399

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 544

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 544
Study: 22081481

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg daily
Number of subjects: 568

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 568
Study: 19084393

Group type: EXPERIMENTAL
Intervention: Capecitabine and oxaliplatin (CAPOX)
Number of subjects: 91
Study: 17403312

Group type: EXPERIMENTAL
Intervention: Propofol (60 ml/min)
Number of subjects: 160
Study: 15188109

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of tranexamic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study: 11384785

Group type: EXPERIMENTAL
Intervention: Adaptive clinical trials (ACTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study: 9705731

Group type: EXPERIMENTAL
Intervention: Top-down encoding with explicit instructions to attend to the relevant feature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal attention conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit instructions or other factors
Number of subjects: 0
Study: 8198894

Group type: EXPERIMENTAL
Intervention: Manual measurement of QT interval with greater amplifier gain
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Manual measurement of QT interval at slower paper speeds
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Manual measurement of QT interval by different cardiologists
Number of subjects: 8
Study: 2642497

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (900 micrograms/m2 subcutaneously twice weekly for eight doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (same schedule as thymosin alpha 1)
Number of subjects: 90
Study: 978238

Group type: EXPERIMENTAL
Intervention: Compensate for arm deflection instruction
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Do not intervene voluntarily instruction
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Increased force disturbance
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Decreased force disturbance
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Symmetric disturbances
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 23
Study: 31532035

Group type: EXPERIMENTAL
Intervention: Home care nursing programme (A)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Standard care (B)
Number of subjects: 378
Study: 31568997

Group type: EXPERIMENTAL
Intervention: Integrated home-visitation program delivered by community health workers including psychosocial stimulation and health promotion during bi-weekly home visits over one year.
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group received no home visits.
Number of subjects: 449
Study: 28577682

Group type: EXPERIMENTAL
Intervention: CR+DHI (Digital Health Intervention)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard CR (Control)
Number of subjects: 80
Study: 25056665

Group type: EXPERIMENTAL
Intervention: Basic intervention (communication of sleep test results and importance of CPAP adherence)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 321
Study: 22915172

Group type: EXPERIMENTAL
Intervention: Tethered swimming (SW)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cycling (CY)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Arm cranking (AC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Running (RU)
Number of subjects: 12
Study: 21302042

Group type: EXPERIMENTAL
Intervention: 40 mg of enteric-coated pantoprazole
Number of subjects: 20
Study: 19319218

Group type: EXPERIMENTAL
Intervention: Family psychoeducation and support group (n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine care group (n = 34)
Number of subjects: 68
Study: 16186075

Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐estradiol (Aerodiol) administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12519853

Group type: EXPERIMENTAL
Intervention: Goserelin acetate 3.6 mg by sc injection every 4 weeks for 12 weeks (Group 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Goserelin plus transdermal testosterone (Androderm 5 mg topically daily) (Group 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Goserelin plus testosterone plus an aromatase inhibitor (anastrozole 1 mg orally daily) (Group 3)
Number of subjects: 70
Study: 10992176

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (2 mg 17beta-estradiol plus 1 mg norethindrone acetate daily)
Number of subjects: 100
Study: 8773422

Group type: EXPERIMENTAL
Intervention: Advantage 24 applied at 15-30 minutes before intercourse
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conceptrol applied at 15-30 minutes before intercourse
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Advantage 24 applied at 12 hours before intercourse
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Advantage 24 applied at 24 hours before intercourse
Number of subjects: 139
Study: 1475038

Group type: EXPERIMENTAL
Intervention: 3 x 0.25 mg rolipram/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3 x 0.50 mg rolipram/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3 x 1.00 mg rolipram/day
Number of subjects: 58
Study: 6427826

Group type: EXPERIMENTAL
Intervention: Cigarettes with varying nicotine and tar yields
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-smoking control condition
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Higher nicotine yielding cigarettes
Number of subjects: 25
Study: 30839067

Group type: EXPERIMENTAL
Intervention: Home-based telehealth (HBT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: In-home-in-person (IHIP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Office-based telehealth (OBT)
Number of subjects: 180
Study: 28856388

Group type: EXPERIMENTAL
Intervention: Polidocanol injections
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lidocaine (placebo)
Number of subjects: 48
Study: 26598571

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment schedules (specific dosage and duration not mentioned)
Number of subjects: 11964
Study: 24599454

Group type: EXPERIMENTAL
Intervention: Rhythmic visual stimuli presented in one visual hemifield
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arhythmic visual stimuli presented in the other visual hemifield
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stronger alpha entrainment
Number of subjects: 0
Study: 22993930

Group type: EXPERIMENTAL
Intervention: Clarithromycin plus standard antibacterial therapy (3rd generation cephalosporins)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard antibacterial therapy (3rd generation cephalosporins)
Number of subjects: 25
Study: 19915829

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg (nighttime dosing)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg (daytime dosing)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of nighttime vs daytime dosing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 14